Real-World Outcomes of Pembrolizumab in Advanced Melanoma by Age and Sex: A National Population-Based Study
Our findings align with clinical trials, demonstrating similar survival outcomes. Younger patients benefited more from pembrolizumab, while female individuals had shorter treatment durations. Further research is required to explore immune checkpoint inhibitor efficacy, safety, and treatment disparities.
Authors
- Chin Hang Yiu (ORCID: https://orcid.org/0000-0001-7758-6087)
- Alexander Maxwell Menzies (ORCID: https://orcid.org/0000-0001-5183-7562)
- Christine Y. Lu (ORCID: https://orcid.org/0000-0002-7550-6837)
Institutions
- The University of Sydney (AU)
- Royal North Shore Hospital (AU)
- Melanoma Institute Australia (AU)
- Northern Sydney Local Health District (AU)
Publication Details
- Journal
- Targeted Oncology
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1007/s11523-025-01164-2
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- University of Sydney